J&J cuts $3.3bn deal to buy eye drug developer Ollin

News
J&J

Johnson & Johnson has agreed to buy Texas biotech Ollin Biosciences for $2.2 billion upfront, adding a keenly anticipated therapy for ophthalmic disorders.

At the heart of the deal – which could be worth up to $3.3 billion if potential milestone payments are factored in – is a clinical-stage candidate for wet age-related macular degeneration (wAMD) and diabetic macular oedema (DME) that has been tipped as a potential rival to Roche's blockbuster Vabysmo (faricimab).

Like Vabysmo, which is on track to reach $5 billion in sales this year, Ollin's OLN324 is a VEGF/Ang2-targeting bispecific antibody but could offer greater potency, according to the Austin-based company.

In a phase 1b trial, OLN324 outperformed Vabysmo in both wAMD and DME, offering faster and greater improvement in pathological changes in the eye and improvements in vision, whilst also requiring fewer doses. Ollin – which licenses OLN324 from China's Innovent – raised an impressive $330 million in Series B financing in June on the back of that preliminary data.

AMD and DME represent a massive market opportunity, as they collectively affect more than 40 million people worldwide and are leading causes of vision loss.

Alongside its proposed acquisition of Ollin, J&J has also entered into a separate risk-sharing deal with private equity group Blackstone Life Sciences to provide funding for a phase 3 trials programme for OLN324, assuming the takeover completes.

Under that agreement, Blackstone would provide $750 million in funding for J&J over several years to advance the drug, in the hope of earning regulatory and sales milestone payments and royalties on sales if it reaches the market. It comes shortly after Blackstone signed a $1.5 billion risk-sharing agreement with Pfizer to fund phase 3 development of its obesity candidate berobenatide.

"OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control," said Kip Connor, head of ophthalmology at J&J.

Ollin's pipeline also includes a preclinical-stage asset, OLN102, which is a bispecific antibody targeting IGF-1R and TSHR and is being developed for thyroid eye disease (TED).

"The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients," he added.

J&J is a major player in the eye care business with its vision and surgical care businesses, which provide products like contact lenses and replacement lenses, and was also developing gene therapies for retinal diseases before they ran into problems in clinical trials and were discontinued.

The deal is expected to close before the end of the year, subject to the usual regulatory approvals and closing conditions.